TY - JOUR

T1 - Trace Amine-associated Receptors (TAARs)

T2 - Candidate Targets in the Treatment of Bipolar Disorders

AU - Альнефеси, Язен А Ф А

AU - Муртазина, Рамиля Зуфаровна

AU - Гайнетдинов, Рауль Радикович

PY - 2025/10/5

Y1 - 2025/10/5

N2 - There is a need for new medications in the treatment of bipolar disorders. One such prospect is the development of ligands for the trace amine-associated receptors (TAARs). There are six functional TAARs in humans (TAAR1, TAAR2, TAAR5, TAAR6, TAAR8 and TAAR9), four of which are expressed at low levels in key areas of the limbic system. Ulotaront is a TAAR1 agonist that has advanced to Phase III with Food and Drug Administration (FDA) breakthrough status in schizophrenia. The drug is now also undergoing clinical development for both major depressive disorder (MDD) and generalized anxiety disorder (GAD). Herein, we review all currently available data that link the TAARs with common abnormalities in bipolar disorders. Some members of the TAAR family regulate fundamental neurological functions such as plasticity, adult neurogenesis, response inhibition, in addition to dopamine and serotonin signaling. This constitutes a theoretical basis for transdiagnostic applications. The evidence particularly favors the TAARs as novel targets in the treatment of bipolar disorders, thus warranting a dedicated effort at drug discovery.

AB - There is a need for new medications in the treatment of bipolar disorders. One such prospect is the development of ligands for the trace amine-associated receptors (TAARs). There are six functional TAARs in humans (TAAR1, TAAR2, TAAR5, TAAR6, TAAR8 and TAAR9), four of which are expressed at low levels in key areas of the limbic system. Ulotaront is a TAAR1 agonist that has advanced to Phase III with Food and Drug Administration (FDA) breakthrough status in schizophrenia. The drug is now also undergoing clinical development for both major depressive disorder (MDD) and generalized anxiety disorder (GAD). Herein, we review all currently available data that link the TAARs with common abnormalities in bipolar disorders. Some members of the TAAR family regulate fundamental neurological functions such as plasticity, adult neurogenesis, response inhibition, in addition to dopamine and serotonin signaling. This constitutes a theoretical basis for transdiagnostic applications. The evidence particularly favors the TAARs as novel targets in the treatment of bipolar disorders, thus warranting a dedicated effort at drug discovery.

KW - Bipolar Disorder/drug therapy

KW - Humans

KW - Receptors, G-Protein-Coupled/agonists

KW - Trace Amine-Associated Receptors

UR - https://www.mendeley.com/catalogue/735ecf82-1033-3054-afc1-daba00bccbb9/

U2 - 10.62641/aep.v53i5.1916

DO - 10.62641/aep.v53i5.1916

M3 - Review article

C2 - 41117250

VL - 53

SP - 1140

EP - 1153

JO - Actas Espanolas de Psiquiatria

JF - Actas Espanolas de Psiquiatria

SN - 1139-9287

IS - 5

ER -